74 completed. 74 Phase 2, 11 Phase 3, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 74 | Completed 74 |
| Phase 3 | 11 | Completed 11 |
| Phase 1 | 7 | Completed 7 |
Follow Thromboembolism: new trials by email Literature Review of Thromboembolism trials Research Report on Thromboembolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) REGN9933, REGN7508, Placebo - Venous Thromboembolism | Phase 2 | Completed | Regeneron Pharmaceuticals | 195 | 2024-09-20 | 2026-04-13 |
| A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants REGN7508, Enoxaparin - Venous Thromboembolism | Phase 2 | Completed | Regeneron Pharmaceuticals | 179 | 2024-06-27 | 2026-05-27 |
| Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair Tirofiban, aspirin, clopidogrel - Unruptured Intracranial Aneurysm, Flow Diverter | Phase 2 / Phase 3 | Completed | Beijing Tiantan Hospital | 192 | 2024-03-04 | 2025-12-11 |
| Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery Enoxaparin - Thromboembolism | Phase 2 | Completed | University of Utah | 64 | 2023-10-11 | 2025-09-04 |
| A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants REGN9933, Enoxaparin, Apixiban - Venous Thromboembolism | Phase 2 | Completed | Regeneron Pharmaceuticals | 373 | 2023-05-24 | 2025-08-29 |
| Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease | Phase 1 / Phase 2 | Completed | University of Aarhus | 57 | 2021-03-25 | 2025-04-11 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet - Venous Thromboembolism, Anticoagulant-induced Bleeding | Phase 2 / Phase 3 | Completed | Instituto Mexicano del Seguro Social | 58 | 2021-01-03 | 2022-08-25 |
| Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe - Venous Thromboembolism | Phase 1 / Phase 2 | Completed | Stanford University | 82 | 2020-08-12 | 2025-06-22 |
| Study of Rivaroxaban for CeREbral Venous Thrombosis Rivaroxaban, Standard of care - Cerebral Venous Thrombosis | Phase 2 | Completed | University of British Columbia | 55 | 2019-03-12 | 2022-12-14 |
| Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement SelK2, Enoxaparin - Venous Thromboembolism | Phase 2 | Completed | Tetherex Pharmaceuticals Corporation | 207 | 2019-02-20 | 2021-01-06 |
| Risk Stratification Procedure for Thromboembolism Prophylaxis acetylsalicylic acid - Total Knee Replacement Surgeries | Phase 2 | Completed | Ministry of Health, Saudi Arabia | 242 | 2018-10-10 | 2020-02-25 |
| Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery Rivaroxaban 10 MG Oral Tablet [Xarelto] - Bariatric Surgery | Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 272 | 2018-07-19 | 2024-11-13 |
| Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma Enoxaparin - Venous Thromboembolism, Deep Vein Thrombosis | Phase 2 | Completed | University of Utah | 80 | 2017-11-15 | 2024-01-31 |
| FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty Enoxaparin, Apixaban, BAY1213790 - Knee Arthroplasty, Total | Phase 2 | Completed | Bayer | 813 | 2017-09-21 | 2020-03-03 |
| Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients Fixed Dose Enoxaparin, Variable Dose Enoxaparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 2 | Completed | University of Utah | 131 | 2017-09-15 | 2020-07-08 |
| Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery Fixed dose, Variable dose - Venous Thromboembolism, Deep Venous Thrombosis | Phase 2 | Completed | University of Utah | 295 | 2017-07-03 | 2020-09-16 |
| Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism Apixaban - Venous Thromboembolism | Phase 2 | Completed | New York Medical College | 25 | 2017-06-02 | 2022-10-25 |
| RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Apixaban, Rivaroxaban - Venous Thromboembolism, Menstruation | Phase 2 / Phase 3 | Completed | Indiana University | 19 | 2016-09-01 | 2023-11-13 |
| Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism DS-1040b, Placebo, Enoxaparin - Pulmonary Embolism, Thrombotic Disease | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 134 | 2016-06-23 | 2023-04-19 |
Showing 20 of 74. Sign in to see all of them.
Venous Thromboembolism (53) · Venous Thrombosis (18) · Pulmonary Embolism (12) · Atrial Fibrillation (7) · Thrombosis (5) · Stroke (3) · Embolism and Thrombosis (2) · Hemorrhage (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Embolism (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1)
Cardiovascular Diseases (74) · Vascular Diseases (74) · Embolism and Thrombosis (72) · Thrombosis (17) · Embolism (12) · Lung Diseases (12) · Respiratory Tract Diseases (12) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (10) · Arrhythmias, Cardiac (7) · Heart Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Brain Diseases (5)
Enoxaparin (26) · Rivaroxaban (13) · apixaban (9) · Warfarin (8) · Aspirin (6) · Dalteparin (6) · Dabigatran (5) · Tablets (3) · edoxaban (3) · Clopidogrel (2) · Fondaparinux (2) · Heparin (2) · Tinzaparin (2) · enoxaparin sodium (2) · 1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1H)-one (1)
Bayer (8) · Astellas Pharma Inc (6) · Boehringer Ingelheim (6) · University of Utah (5) · Daiichi Sankyo (3) · Ottawa Hospital Research Institute (3) · Regeneron Pharmaceuticals (3) · Daiichi Sankyo Co., Ltd. (2) · GlaxoSmithKline (2) · Hamilton Health Sciences Corporation (2) · McMaster University (2) · Sanofi (2) · Astellas Pharma Europe B.V. (1) · Beijing Tiantan Hospital (1) · CONKO-Studiengruppe (1)
United States (27) · Canada (24) · Poland (15) · Russia (14) · Denmark (12) · Israel (11) · Italy (11) · Austria (10) · Latvia (10) · Norway (10) · Spain (10) · Sweden (10) · Bulgaria (9) · France (9) · Germany (9)
Christopher Puccini, MD (3) · Sam Schulman, MD, PhD (2) · Akihiko Taguchi, MD.PhD (1) · Ann Bruno, MD (1) · Anthony Maraveyas (1) · Arash Momeni, MD (1) · Aurelien Delluc, MD, PhD (1) · Barbara A. Conley, MD (1)
PMID 33086312, PMID 31420317, PMID 33337539, PMID 41218619, PMID 18088349, PMID 18402906, PMID 18621928, PMID 19187076, PMID 19640572, PMID 19854398, PMID 20448094, PMID 20886185, PMID 22100906, PMID 22284935, PMID 22431865, PMID 24136153, PMID 24232703, PMID 24641937, PMID 24837794, PMID 25047458, PMID 25482425, PMID 26688233, PMID 27075710, PMID 27357738, PMID 29452956, PMID 29649055, PMID 30511879, PMID 31324209, PMID 31935028, PMID 32045583, PMID 32589230, PMID 32641236, PMID 32827160, PMID 33029262, PMID 33857789, PMID 34622445, PMID 35124234, PMID 35660801, PMID 35678616, PMID 36413425, PMID 37227726, PMID 37675613, PMID 38189593, PMID 38957026, PMID 40478760, PMID 41333097, PMID 42283072
2014 (3), 2016 (2), 2023 (2), 2005 (1), 2008 (1), 2009 (1), 2015 (1), 2018 (1), R42HL086316 (1)